Concepedia

Publication | Closed Access

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target

DOI

116

Citations

38

References

2016

Year

Alfredo Perales‐Puchalt, Nikolaos Svoronos, Melanie R. Rutkowski, Michael J. Allegrezza, Amelia J. Tesone, Kyle K. Payne, Jayamanna Wickramasinghe, Jenny Nguyen, Shane W. O’Brien, Kiranmai Gumireddy,
Clinical Cancer Research

Abstract

T cells redirected against FSHR<sup>+</sup> tumor cells with full-length FSH represent a promising therapeutic alternative against a broad range of ovarian malignancies, with negligible toxicity even in the presence of cognate targets in tumor-free ovaries. Clin Cancer Res; 23(2); 441-53. ©2016 AACR.

References

YearCitations

Page 1